Scarica l'app Stockscreener
9.04
3.08%
0.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ETNB Giù?
Forum
Previsione
Precedente Chiudi:
$8.77
Aprire:
$8.84
Volume 24 ore:
1.30M
Relative Volume:
0.71
Capitalizzazione di mercato:
$1.32B
Reddito:
-
Utile/perdita netta:
$-174.61M
Rapporto P/E:
-4.5888
EPS:
-1.97
Flusso di cassa netto:
$-165.54M
1 W Prestazione:
-6.71%
1M Prestazione:
-17.82%
6M Prestazione:
-17.89%
1 anno Prestazione:
+15.60%
Intervallo 1D:
$8.72
$9.245
Intervallo di 1 settimana:
$8.4207
$10.32
Portata 52W:
$4.16
$11.84
89 Bio Inc Stock (ETNB) Company Profile
Nome
89 Bio Inc
Settore
Industria
Telefono
(415) 432-9270
Indirizzo
655 MONTGOMERY STREET, SAN FRANCISCO, CA
Confronta ETNB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
9.04 | 1.30B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Ripresa | BofA Securities | Buy |
| 2024-01-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-06-13 | Iniziato | Evercore ISI | Outperform |
| 2022-05-12 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-26 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-19 | Iniziato | Raymond James | Strong Buy |
| 2020-09-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-23 | Iniziato | BTIG Research | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2019-12-09 | Iniziato | BofA/Merrill | Neutral |
| 2019-12-09 | Iniziato | Oppenheimer | Outperform |
| 2019-12-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-12-09 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
89 Bio Inc Borsa (ETNB) Ultime notizie
89bio Inc. recovery potential after sell offBuy Candidate Summary Based on Fundamentals - Newser
89Bio Inc. Faces Financial Uncertainty Amid Potential U.S. Tax Law Changes - TipRanks
How 89bio Inc. stock performs during market volatilityChart Pattern Strategy with ROI Focus - Newser
Chart based exit strategy for 89bio Inc.Free Entry Alert Based on Volume Spikes - Newser
Can trapped investors hope for a rebound in 89bio Inc.Retirement Investment Outlook and Return Summary - Newser
Quantitative breakdown of 89bio Inc. recent moveLow Risk Strategy with Smart Entry Zones - Newser
Evaluating 89bio Inc. with trendline analysisBuy Strategy with Smart Exit Timing - Newser
Analyzing recovery setups for 89bio Inc. investorsFree Real Time Alerts Based on AI Prediction - Newser
89bio: Promising As Pegozafermin Nears Phase 3 Readout (NASDAQ:ETNB) - Seeking Alpha
What makes 89bio Inc. stock price move sharplyFree Triple Return Setup with Risk Control - Newser
Signal strength of 89bio Inc. stock in tech scannersFree Community Verified Stock Suggestions - Newser
How to track smart money flows in 89bio Inc.Free Intraday Trend Analysis for Fast Gains - Newser
Statistical indicators supporting 89bio Inc.’s strengthValue Investing Summary and Earnings Outlook - Newser
Advanced analytics toolkit walkthrough for 89bio Inc.Risk Balanced Picks for Safer Trading - Newser
How moving averages guide 89bio Inc. tradingAI Trade Signal Forecast with Chart Logic - Newser
89Bio Inc. Faces Financial Uncertainty Amid U.S. Tax Law Changes - AInvest
Using Bollinger Bands to evaluate 89bio Inc.Momentum Detection with Entry Optimization - Newser
What institutions are buying 89bio Inc. stock nowFree Pattern Alert With ROI Driven Strategy - Newser
What moving averages say about 89bio Inc.Predictive System for Long-Term Stock Forecast - Newser
How to read the order book for 89bio Inc.Swing Trade Entry and Exit Point Analysis - Newser
89bio, Inc. SEC 10-Q Report - TradingView
89Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
89bio (ETNB) Q2 R&D Jumps 131% - The Motley Fool
89Bio Inc.’s ENTRUST Study: A Potential Game-Changer in Hypertriglyceridemia Treatment - TipRanks
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates - The Manila Times
89bio Q2 Earnings Reveal Massive $561M War Chest for Game-Changing MASH Treatment Trials - Stock Titan
Custom strategy builders for tracking 89bio Inc.Near-Term Market Opportunity Forecast Sheet - Newser
Can 89bio Inc. stock recover from recent declineEarly Entry Planner for Swing Candidates - Newser
Allianz Asset Management GmbH Invests $93,000 in 89BIO (NASDAQ:ETNB) - Defense World
How to monitor 89bio Inc. with trend dashboardsFree Capital Efficiency Optimized Stock Alerts - Newser
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
89bio Awards Major Stock Options Package: 267,000 Shares to 3 New Hires in Liver Disease Research Push - Stock Titan
89 Bio Inc Azioni (ETNB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):